Targeting brain metastases in advanced NSCLC: The emerging impact of ADCs

touchEXPERT FOCUS for touchENDOCRINOLOGY Listen to a series of short interviews with paediatric endocrinologist Dr Ashley Shoemaker as she discusses the clinical manifestations and pathophysiology of Prader–Willi syndrome (PWS), with a focus on hyperphagia by exploring the spectrum across the lifespan of PWS and shares best practices for managing PWS-related hyperphagia within a multidisciplinary framework. The expert: Dr Ashley Shoemaker, Vanderbilt University Medical Center, Nashville, TN, USA This touchPODCAST is for HCPs in the USA only. This activity is funded by an independent medical education grant from Soleno Therapeutics. The activity is jointly provided by Partners for Advancing Clinical Education (Partners) and touchIME.   For further information, visit our website: https://touchendocrinologyime.org/hyperphagia-pws-recognition-management/

touchPANEL DISCUSSION for touchONCOLOGY and touchRESPIRATORY   Listen to leading experts discuss the role of antibody–drug conjugates (ADCs) in NSCLC with brain metastases, including the latest clinical trial evidence, practical approaches to patient selection and treatment sequencing alongside local CNS therapies, and the evolving pipeline of investigational ADCs. The expert(s) Dr Lyudmila Bazhenova, Moore’s Cancer Center, San Diego, CA, USA Dr Elvire Pons-Tostivint, Nantes Université, Centre Hospitalier Universitaire Nantes, France Dr Julia Rotow, Dana-Farber Cancer Institute, Boston, MA, USA This touchPODCAST is for HCPs only outside of the UK. This activity is funded by an independent medical education grant fromAstraZeneca. This activity is jointly provided by USF Health and touchIME.  touchIME is an EBAC® accredited provider. For further information visit our websites:  www.touchONCOLOGY.com www.touchRESPIRATORY.com

touchPANEL DISCUSSION for touchHAEMATOLOGY and touchONCOLOGY Listen to a panel of leading experts as they explore the latest advances in PNH pathophysiology, diagnostic approaches and therapeutic strategies, including data from ASH 2025, with practical insights for contemporary clinical practice. The experts: Prof. Bruno Fattizzo, Università degli Studi di Milano, Milan, Italy Dr Austin Kulasekararaj, King’s College Hospital NHS Foundation Trust, London, UK Dr Srikanth Nagalla, Miami Cancer Institute, Miami, FL, USA This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Alexion Pharma GmbH. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchHAEMATOLOGY.com or www.touchONCOLOGY.com

touchCASES for touchNEUROLOGY, touchCARDIO, touchENDOCRINOLOGY and touchRESPIRATORY Listen to two experts as they discuss three cases illustrating the heterogeneous, multisystem nature of late-onset Pompe disease (LOPD). They examine key decision points from recognizing early clinical clues and confirming diagnosis to optimizing enzyme replacement therapy (ERT), monitoring progression and coordinating multidisciplinary, patient-centred care.  The experts: Prof. John Vissing, University of Copenhagen, Copenhagen, Denmark Prof. Pascal Laforêt, Versailles-Saint Quentin University, Versailles, France  This activity is for HCPs outside of the USA. This activity is supported by an independent educational grant from Amicus Therapeutics UK LTD. touchIME is an EBAC® accredited provider. For further information visit our websites:  touchNEUROLOGY -  https://touchneurologyime.org/diagnosis-monitoring-management-lopd/ touchCARDIO - https://touchcardioime.org/diagnosis-monitoring-management-lopd/ touchENDOCRINOLOGY - https://touchendocrinologyime.org/diagnosis-monitoring-management-lopd/ touchRESPIRATORY - https://touchrespiratoryime.org/diagnosis-monitoring-management-lopd/  

touchCONGRESS for touchHAEMATOLOGY and touchONCOLOGY Listen to multiple myeloma expert Dr Rakesh Popat review key data for BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma presented at the International Multiple Society (IMS) and American Society of Hematology (ASH) 2025 congresses. Dr Popat is then joined by fellow experts Dr Paula Rodríguez-Otero and Dr Roberto Mina to discuss the implications of these data for current and future clinical practice.   Overview Data reviews with Dr Popat Expert panel discussions with Dr Popat, Dr Rodríguez-Otero and Dr Mina on the themes below Clinical themes Approved BCMA-directed therapeutic approaches  Practical application of BCMA-directed therapies Future of treating RRMM: Emerging BCMA-directed therapies and combinations The internationally renowned multiple myeloma expert faculty Dr Rakesh Popat: London, UK Dr Paula Rodríguez-Otero: Pamplona, Spain Dr Roberto Mina: Atlanta, GA, USA This touchPODCAST is for HCPs outside of the USA.  This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information, visit our website: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com

touchEXPERT FOCUS for touchONCOLOGY Listen to insights from Dr Kathleen Moore on the pathophysiology and molecular features of low-grade serous ovarian cancer (LGSOC) and how it differs from other ovarian cancers. She also discusses evidence-based treatment options and sequencing, as well as practical considerations relating to administration and side-effect management. The expert: Dr Kathleen Moore, OH Health Stephenson Cancer Center, Oklahoma City, OK, USA This touchPODCAST is for HCPs in the USA only. This activity is funded by an independent medical education grant from Verastem, Inc. The activity is jointly provided by Partners for Advancing Clinical Education and touchIME. For further information visit our website: www.touchONCOLOGY.com

touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Nicholas Girard, Institut Curie, Paris, France   Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets In this module, Professor Pasi Jänne and Dr. Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA   Module 3: Targeting resistance in EGFR-mutant NSCLC: The role of biomarkers In this module, Professor Pasi Jänne and Professor Paul Hofman explore how precision medicine and molecular resistance mechanisms are shaping testing strategies. They discuss the role of biomarkers, evolving guideline recommendations and how clinicians can adapt testing approaches to align with new targeted therapies. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Paul Hofman, University Côte d’Azur, Nice, France.     This touchPODCAST is for HCPs only. This activity is funded by an educational grant from AstraZeneca Ltd.  This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:   https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/ https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/  

touchIN CONVERSATION for touchHAEMATOLOGY The presence of anaemia and/or thrombocytopenia complicates the management of patients with myelofibrosis (MF). Listen to expert haematologists consider the burden of cytopenias in patients with MF and discuss strategies to reduce transfusion dependence, improve splenomegaly and personalize treatment with JAK inhibitors. The experts Prof. Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK Dr Laura Fox, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain This touchPODCAST is for HCPs outside of the USA. This activity is supported by an independent medical education grant from GSK. This activity is provided by touchIME in collaboration with our Education Partner Haematology Nurses & Healthcare Professionals Group (HNHCP). touchIME is an EBAC® accredited provider. For further information visit our website: www.touchHAEMATOLOGY.com

touchEXPERT FOCUS for touchHAEMATOLOGY and touchONCOLOGY Listen to a series of short interviews with three leading experts who provide their insights into early-line management of chronic myeloid leukaemia and the impact on quality of life. The experts: Dr Delphine Rea, Hôpital Saint-Louis, Paris, France  Prof. Andreas Hochhaus, Jena University Hospital, Jena, Germany Prof. Etab Atallah, Medical College of Wisconsin, Milwaukee, WI, USA This activity is for healthcare professionals outside of the USA and UK. This independent medical education is supported by Novartis and is provided by touchIME. For further information visit our website: www.touchHAEMATOLOGY.com or www.touchONCOLOGY.com

touchTALKS for touchONCOLOGY Listen to Dr Christine Bestvina, as she evaluates the latest data on KRAS mutations in NSCLC and explores how emerging evidence for targeted therapies could influence clinical decision-making. The expert Dr Christine Bestvina, University of Chicago, Chicago, IL, USA This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Revolution Medicines. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.  For further information visit our website: www.touchONCOLOGY.com